Stock Comparison

TALK vs TDOC

Talkspace Inc vs Teladoc Health Inc

Who's the better investment? Let's break it down.

The Verdict

TDOC takes this one.

It's not even close. TDOC outscores TALK by 3.8 points. That's a significant gap in our deep value framework.

TALK

Talkspace Inc

0.5

out of 10

Distressed

Winner

TDOC

Teladoc Health Inc

4.3

out of 10

Proceed with Caution

Want to compare any two stocks?

Valuation

TALK

Metric

TDOC

$851M

Market Cap

$1.4B

102.8

P/E Ratio

Lower may indicate better value

2.0

0.0

Forward P/E

2.0

0.0

Price/Book

1.0

0.0

EV/EBITDA

37.1

Profitability & Growth

TALK

Metric

TDOC

3.4%

Profit Margin

-6.8%

60.0%

Gross Margin

69.3%

0.0%

Operating Margin

-8.1%

7.0%

Return on Equity

-12.4%

0.0%

Return on Assets

-6.0%

22.0%

Revenue Growth

-1.5%

$0.05

EPS

$-0.96

Financial Health

TALK

Metric

TDOC

0.0

Debt-to-Equity

Lower = less leverage

0.7

0.0

Current Ratio

Above 1.0 is healthy

2.8

1.2

Beta

Lower = less volatile

2.1

None

Dividend Yield

None

Risk Comparison

TALK

Overall

Moderate

Financial

Low

Market

Low

Competitive

Low

Execution

Low

Regulatory

Medium

What Could Go Wrong

The acquisition by Universal Health Services for $5.25 per share could fail to close if regulatory approvals are not granted or if shareholder opposition (like the Ademi Firm's investigation) leads to...

Red Flags

🚩Acquisition caps all public equity upside to $5.25/share.
🚩Shareholder investigation by Ademi Firm into fair price and insider benefits.

TDOC

Overall

Aggressive

Financial

High

Market

Medium

Competitive

High

Execution

High

Regulatory

Medium

What Could Go Wrong

Teladoc's core BetterHelp segment continues to weaken and face pricing pressure from 'better-for-less costly telehealth alternatives,' leading to an accelerating -2.5% YoY revenue decline and persiste...

Red Flags

🚩Q1 2026 Revenue declined 2.5% YoY, indicating erosion of market position and challenge in achieving ...
🚩Q1 2026 Free Cash Flow was an outflow of -$26.3 million, signaling continued cash burn despite effic...
🚩Jefferies' price target of $6, raised post-Q1 earnings, is below the current market price of $7.61, ...

Competitive Moat

TALK

Rating

🛡️ Narrow

Trend

📈 Expanding

Brand PowerSwitching Costs (for enterprise clients/payers)Network Effects (provider-patient matching)

TDOC

Rating

🛡️ Narrow

Trend

➡️ Eroding

Switching Costs (for large enterprise clients integrating Teladoc's platform into their benefits programs).Network Effects (more providers attract more members, improving access and service quality).Intangible Assets/IP (proprietary platform, data-driven insights, clinical guidelines).

Investment Thesis

TALK0.5/10

The investment thesis for Talkspace has shifted from a high-growth, turnaround play to a pure arbitrage opportunity. The company, having successfully pivoted to B2B and achieved adjusted EBITDA profitability, attracted an acquisition offer from UHS at $5.25/share. For current public shareholders, the focus is now on the successful closing of this cash acquisition, not on future independent growth ...

Full TALK Analysis

TDOC4.3/10

If Teladoc successfully pivots its BetterHelp segment through strategic repositioning and cost efficiencies, while simultaneously accelerating chronic care management revenue via new large employer/payer contracts (e.g., >$50M annual contract), then it could re-accelerate overall revenue growth to 5%+ YoY and achieve positive free cash flow, justifying a P/S multiple re-rating from 0.4x to 2.0x wi...

Full TDOC Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

TALK0.5/10

The definitive agreement for Universal Health Services (UHS) to acquire Talkspace (TALK) for $5.25 per share fundamentally alters its investment profile. While the company demonstrated strong Q4 2025 earnings, positive adjusted EBITDA, and a robust balance sheet, the stock's upside is now capped at the acquisition price, effectively eliminating any potential for a 10x return as an independent public entity. The previous score reflected the company's significant turnaround and growth potential; h...

Full TALK Analysis

TDOC4.3/10

Teladoc Health operates in a vast virtual care market with a compelling whole-person health vision, but recent Q1 2026 results show significant headwinds. Revenue declined 2.5% YoY, and free cash flow was a notable -$26.3 million outflow, indicating persistent cash burn and challenging top-line execution. While operating margins improved, overall profitability remains elusive. Competitive advantages are not expanding in a crowded market, and analyst sentiment, as seen with Jefferies' sub-market ...

Full TDOC Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.